{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:47:39Z","timestamp":1785840459200,"version":"3.56.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In biologic therapies targeting interleukin (IL)-23 for plaque psoriasis, parenteral administration can limit treatment adherence and quality of life. Icotrokinra is a first-in-class oral peptide that selectively antagonizes the IL-23 receptor and has shown promising efficacy in phase II and phase III trials. However, a comprehensive synthesis of efficacy and safety across these trials is currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of icotrokinra in adolescents (12\u201317\u2005years) and adults (\u2265 18\u2005years) with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched on 8 December 2025, with reference lists hand-searched for additional studies. Randomized controlled trials enrolling the target population were included if they compared icotrokinra with placebo and reported efficacy or safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five randomized controlled trials (one phase II and four phase III), comprising four reports, met the inclusion criteria. Icotrokinra significantly increased the likelihood of achieving an Investigator\u2019s Global Assessment score of 0 or 1 at week 16 compared with placebo (risk ratio 7.27, 95% confidence interval 5.80\u20139.11), with no heterogeneity (I2 = 0%). High-level skin clearance, represented by \u2265 90% improvement in Psoriasis Area and Severity Index, was also significantly improved (risk ratio 13.8, 95% confidence interval 7.21\u201326.5). Rates of treatment-emergent and serious adverse events were comparable between icotrokinra and placebo, with no new safety signals identified over the 16-week trial period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Icotrokinra has shown short-term efficacy and a favourable safety profile in patients with moderate-to-severe plaque psoriasis. Combining biologic-level efficacy with ease of administration, icotrokinra may represent an important advance in psoriasis therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag255","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:40:27Z","timestamp":1781613627000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9220-9204","authenticated-orcid":false,"given":"Sunaina","family":"Advani","sequence":"first","affiliation":[{"name":"School of Medicine, University of Connecticut School of Medicine , Farmington, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4447-0665","authenticated-orcid":false,"given":"Advait","family":"Raja","sequence":"additional","affiliation":[{"name":"Clinical School of Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0276-6186","authenticated-orcid":false,"given":"Tatiana","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Medicina Intensiva del Tolima, UCI Honda , Honda ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmeyye","family":"Akta\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Necmettin Erbakan University Faculty of Medicine , Konya ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayomide","family":"Lawal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mid and South Essex NHS Foundation Trust , Essex ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9063-8554","authenticated-orcid":false,"given":"Alfonso","family":"Gotor","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital \u201812 de Octubre\u2019 , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026080406065631400_llag255-B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2026080406065631400_llag255-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"2026080406065631400_llag255-B3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"2026080406065631400_llag255-B6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"2026080406065631400_llag255-B7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026080406065631400_llag255-B8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026080406065631400_llag255-B9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.12276","article-title":"Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses","volume":"168","author":"Samarasekera","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B12","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026080406065631400_llag255-B13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2026080406065631400_llag255-B14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab vs. placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2026080406065631400_llag255-B16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD\u2013NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2026080406065631400_llag255-B19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjd.12745","article-title":"Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice","volume":"170","author":"Duffin","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080406065631400_llag255-B21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","article-title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials","volume":"406","author":"Stein Gold","year":"2025","journal-title":"Lancet"},{"key":"2026080406065631400_llag255-B22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","article-title":"Oral icotrokinra for plaque psoriasis in adults and adolescents","volume":"393","author":"Bissonnette","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080406065631400_llag255-B23","doi-asserted-by":"crossref","first-page":"EVIDoa2500155","DOI":"10.1056\/EVIDoa2500155","article-title":"Targeted oral peptide icotrokinra for psoriasis involving high-impact sites","volume":"4","author":"Gooderham","year":"2025","journal-title":"NEJM Evid"},{"key":"2026080406065631400_llag255-B24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026080406065631400_llag255-B25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jrsm.1679","article-title":"A REML method for the evidence-splitting model in network meta-analysis","volume":"15","author":"Piepho","year":"2024","journal-title":"Res Synth Methods"},{"key":"2026080406065631400_llag255-B26","volume-title":"Comparative Effectiveness Review Methods: Clinical Heterogeneity","author":"West"},{"key":"2026080406065631400_llag255-B27","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2024."},{"key":"2026080406065631400_llag255-B28"},{"key":"2026080406065631400_llag255-B29","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"2026080406065631400_llag255-B30","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"2026080406065631400_llag255-B31","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080406065631400_llag255-B32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","article-title":"Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations","volume":"11","author":"Gisondi","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026080406065631400_llag255-B33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B34","doi-asserted-by":"crossref","first-page":"17515","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci Rep"},{"key":"2026080406065631400_llag255-B35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2026080406065631400_llag255-B36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/jdv.12118","article-title":"A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis","volume":"28","author":"Mrowietz","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026080406065631400_llag255-B37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the IL-23\/type 17\u2005T cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu Rev Med"},{"key":"2026080406065631400_llag255-B38","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1007\/s12325-025-03213-8","article-title":"Oral peptide therapeutics as an emerging treatment modality in immune-mediated inflammatory diseases: a narrative review","volume":"42","author":"Stein Gold","year":"2025","journal-title":"Adv Ther"},{"key":"2026080406065631400_llag255-B39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","article-title":"Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents","volume":"16","author":"Drakos","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026080406065631400_llag255-B40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026080406065631400_llag255-B41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung\u2013Knapp\u2013Sidik\u2013Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian\u2013Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026080406065631400_llag255-B42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","article-title":"FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","volume":"92","author":"Ferris","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026080406065631400_llag255-B44","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"2026080406065631400_llag255-B45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"2026080406065631400_llag255-B48","doi-asserted-by":"crossref","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"key":"2026080406065631400_llag255-B49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib vs. placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026080406065631400_llag255-B50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2023.2219054","article-title":"TYK2 as a novel therapeutic target in psoriasis","volume":"16","author":"Elyoussfi","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026080406065631400_llag255-B51","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2026080406065631400_llag255-B52","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Page\u00a0","year":"2024"},{"key":"2026080406065631400_llag255-B53","doi-asserted-by":"crossref","first-page":"e193563","DOI":"10.1172\/jci.insight.193563","article-title":"Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis","volume":"10","author":"Strawn","year":"2025","journal-title":"JCI Insight"},{"key":"2026080406065631400_llag255-B54","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.13437","article-title":"Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response","volume":"172","author":"Signorovitch","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B55","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026080406065631400_llag255-B56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/24755303241303089","article-title":"The FORWARD psoriasis registry: patient-reported outcomes in a novel psoriasis registry and comparison of traditional, dermatologist-led enrollment with web-based patient enrollment","volume":"10","author":"Song","year":"2025","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2026080406065631400_llag255-B57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"key":"2026080406065631400_llag255-B58","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026080406065631400_llag255-B59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag255\/68542849\/llag255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag255\/68542849\/llag255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:07:11Z","timestamp":1785838031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag255\/8709980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag255","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"llag255"}}